NCT03710434 - AZD4635 Relative Bioavailability Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

April 2, 2019

Study Completion Date

April 2, 2019

Conditions

Healthy Volunteers

Interventions

DRUG

AZD4635 50 mg nano-suspension (reference)

Subjects will receive a single dose of AZD4635 50 mg nano-suspension (reference) in the fasted state.

DRUG

AZD4635 solid oral formulation - fasted

Subjects will receive a single dose of AZD4635 solid oral formulation, in the fasted state.

DRUG

AZD4635 solid oral formulation - fed

Subjects will receive a single dose of AZD4635 solid oral formulation, in the fed state.

DRUG

Lansoprazole and AZD4635 50 mg solid oral formulation

Subjects will receive lansoprazole 30 mg BID for 5 days followed by a single dose of AZD4635 50 mg solid oral formulation in the fasted state.

DRUG

AZD4635 solid oral formulation variant 1 - fasted

Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state.

DRUG

AZD4635 solid oral formulation variant 2 - fasted

Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.

DRUG

[14C] AZD4635 IV microtracer - fasted

Subjects will receive a single dose of \[14C\] AZD4635 IV microtracer. This intervention will be co-administered with AZD4635 solid oral formulation variant 1.

Trial Locations (1)

NG11 6JS

Research Site, Ruddington